BACKGROUND: Previous studies have demonstrated that brain-derived neurotrophic factor (BDNF)promotes neural differentiation. However, the mechanisms involved in cell cycle-related proteinregulation, which highly correlates to neural proliferation and apoptosis, remain poorly understood.OBJECTIVE: To investigate the effects of various concentrations of BDNF on cycle-related proteinmRNA expression in induce-differentiated SH-SY5Y cells in vitro prior to and following G_2 phase,and to analyze the neuroprotective effects of BDNF.DESIGN, TIME AND SETTING: A comparison, observational study, based on cell biology, wasperformed at the Department of Biochemistry, Medical College of Tongji University, from March2005 to October 2006.MATERIALS: SH-SY5Y cells were provided by Shanghai Institute of Cytology, Chinese Academy ofScience; BDNF by Alomone Labs, Israel; all-trans retinoic acid (ATRA) by Sigma-Aldrich, USA.METHODS: SH-SY5Y cells were randomly divided into three groups: blank control [cells weretreated in Insulin-Transferrin-Selenium (ITS) solution for 7 days], ATRA (cells were treated with ITSsolution containing 10 μmol/L ATRA for 7 days), and BDNF (cells were treated identical to the ATRAgroup for 5 days, and then respectively treated in ITS solution containing 1, 10, and 100 μg/L BDNFfor 2 days). The experiment was repeated three times for each group.MAIN OUTCOME MEASURES: mRNA expression levels of cyclin A1, B1, B2, cyclin-dependentkinase 1, and 5 were detected using quantitative real-time RT-PCR; percentage of cells in G_1, S, andG_2 phases were detected using fluorescence-activated cell sorting.RESULTS: mRNA expression levels of cyclin A1 in the high-dose BDNF group was significantly lessthan the ATRA group (P < 0.05). mRNA expression levels of cyclin B1 was significantly less in thedifferent BDNF concentration groups compared with the control and ATRA groups (P < 0.05 or P <0.01). mRNA expression levels of cyclin B2 and cyclin-dependent kinase 1 were significantlydecreased in the high-dose BDNF group (P < 0.05 or P < 0.01). Cyclin-dependent kinase 5 mRNAexpression was significantly greater in the low-dose and moderate-dose BDNF groups comparedwith the ATRA group (P < 0.05). The percentage of cells in G1 phase was significantly greater in thedifferent BDNF concentration groups compared with the ATRA and control groups (P < 0.01).Moreover, the percentage of cells in S phase was significantly less in the three BDNF groupscompared with the ATRA group (P < 0.01). However, the percentage of cells in S phase wassignificantly less in the low-dose and high-dose BDNF groups compared with the control group (P <0.01).CONCLUSION: BDNF enhanced the percentage of cells in G_1 phase, but did not alter mRNAexpression of cell cycle-related proteins prior to or following G_2 phase. These results suggested thatBDNF was not a risk factor for inducing apoptosis. BACKGROUND: Previous studies have demonstrated that brain-derived neurotrophic factor (BDNF) promotes neural differentiation. However, the mechanisms involved in cell cycle-related protein regulation, which highly correlates to neural proliferation and apoptosis, remain poorly understood. OBJECTIVE: To investigate the effects of various concentrations of BDNF on cycle-related protein mRNA in in-differentiated SH-SY5Y cells in vitro prior to and following G_2 phase, and to analyze the neuroprotective effects of BDNF. DESIGN, TIME AND SETTING: A comparison, observational study, based on cell biology, wasperformed at the Department of Biochemistry, Medical College of Tongji University, from March 2005 to October 2006.MATERIALS: SH-SY5Y cells were provided by Shanghai Institute of Cytology, Chinese Academy of Sciences; BDNF by Alomone Labs, Israel; all- trans retinoic acid (ATRA) by Sigma-Aldrich, USA. METHODS: SH-SY5Y cells were differentiated into three groups: blank control [cells were treated in Insulin-Transferrin-Selenium (ITS) solution for 7 days], ATRA (cells were treated with ITS solution containing 10 μmol / L ATRA for 7 days), and BDNF (cells were treated identical to the ATRAgroup for 5 days, and then respectively treated in ITS solution containing 1, 10, and 100 μg / L BDNF for 2 days). The experiment was repeated three times for each group. MAIN OUTCOME MEASURES: mRNA expression levels of cyclin A1, B1, B2, cyclin- and 5 were detected using quantitative real-time RT-PCR; percentage of cells in G_1, S, andG_2 phases were detected using fluorescence-activated cell sorting.RESULTS: mRNA expression levels of cyclin A1 in the high-dose BDNF group was significantly lessthan the ATRA group (P <0.05). mRNA expression levels of cyclin B1 were significantly less in the same than BDNF concentration groups compared with the control and ATRA groups (P <0.05 or P <0.01) kinase 1 were significant l(P <0.05 or P <0.01) .Cyclin-dependent kinase 5 mRNA expression was significantly greater in the low-dose and moderate-dose BDNF groups compared with the ATRA group (P <0.05). The percentage of cells in G1 phase was significantly greater in the different BDNF concentration groups compared with the ATRA and control groups (P <0.01) .Moreover, the percentage of cells in S phase was significantly less in the three BDNF groupscompared with the ATRA group (P < 0.01). However, the percentage of cells in S phase wassignificantly less in the low-dose and high-dose BDNF groups compared with the control group (P <0.01) .CONCLUSION: BDNF enhanced the percentage of cells in G_1 phase, but did not alter mRNA expression of cell cycle-related proteins prior to or following G_2 phase. These results suggest thatBDNF was not a risk factor for inducing apoptosis.